IL-17 antagonistic antibodies
An IL-17 binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g. rheumatoid arthritis.
1. A purified IL-17 binding molecule comprising a heavy chain variable domain comprising SEQ ID NO:8.
2. A purified IL-17 binding molecule comprising a light chain variable domain comprising SEQ ID NO:10.
3. A purified IL-17 binding molecule comprising a heavy chain variable domain comprising SEQ ID NO:8 and a light chain variable domain comprising SEQ ID NO:10.
4. A purified IL-17 binding molecule comprising a heavy chain variable domain comprising the three Complementarity-Determining Regions (CDRs) of SEQ ID NO:8 and a light chain variable domain comprising the three CDRs of SEQ ID NO:10.
5. The purified IL-17 binding molecule of claim 4 , wherein said three CDRs of SEQ ID NO:8 are set forth in SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3.
6. The purified IL-17 binding molecule of claim 4 , wherein said three CDRs of SEQ ID NO:8 are set forth in SEQ ID NO:11, SEQ ID NO:12 and SEQ ID NO:13.
7. The purified IL-17 binding molecule of claim 5 , wherein said three CDRs of SEQ ID NO:10 are set forth in SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6.
8. The purified IL-17 binding molecule of claim 6 , wherein said three CDRs of SEQ ID NO:10 are set forth in SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6.
9. The purified IL-17 binding molecule of either claim 7 or 8 , wherein said IL-17 binding molecule is a human antibody.
10. A pharmaceutical composition comprising the purified IL-17 binding molecule of either claim 7 or 8 and a pharmaceutically acceptable diluent, excipient, carrier or mixture thereof.
11. A pharmaceutical composition comprising the purified IL-17 binding molecule of claim 9 and a pharmaceutically acceptable diluent, excipient, carrier or mixture thereof.
12. A method for inhibiting the binding of IL-17 to an IL-17 receptor in a subject, comprising administering to the subject the purified IL-17 binding molecule of either claim 7 or 8 in an amount effective to inhibit the binding of IL-17 to the IL-17 receptor in the subject.
13. A method for inhibiting the binding of IL-17 to an IL-17 receptor in a subject, comprising administering to the subject the purified IL-17 binding molecule of claim 9 in an amount effective to inhibit the binding of IL-17 to the IL-17 receptor in the subject.
14. A method for inhibiting the binding of IL-17 to an IL-17 receptor in a subject, comprising administering to the subject the pharmaceutical composition of claim 11 in an amount effective to inhibit the binding of IL-17 to the IL-17 receptor in the subject.
15. A method for binding IL-17 in a subject, comprising administering to the subject the purified IL-17 binding molecule of either claim 7 or 8 in an amount effective to bind IL-17 in the subject.
16. A method for binding IL-17 in a subject, comprising administering to the subject the purified IL-17 binding molecule of claim 9 in an amount effective to bind IL-17 in the subject.
17. A method for binding IL-17 in a subject, comprising administering to the subject the pharmaceutical composition of claim 11 in an amount effective to bind IL-17 in the subject.
18. A method for treating an IL-17 mediated inflammatory condition or IL-17 mediated autoimmune disease in a subject, comprising administering to the subject in need thereof an effective amount of the purified IL-17 binding molecule of either claim 7 or 8 .
19. A method for treating an IL-17 mediated inflammatory condition or IL-17 mediated autoimmune disease in a subject, comprising administering to the subject in need thereof an effective amount of the purified IL-17 binding molecule of claim 9 .
20. A method for treating an IL-17 mediated inflammatory condition or IL-17 mediated autoimmune disease in a subject, comprising administering to the subject in need thereof an effective amount of the pharmaceutical composition of claim 11 .
21. The method according to claim 19 , wherein said IL-17 mediated inflammatory condition or autoimmune disease is rheumatoid arthritis.
22. The method according to claim 19 , wherein said IL-17 mediated inflammatory condition or autoimmune disease is psoriasis.